The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study.
J. De la Haba
Disclosure not yet available
A. Rodriguez-Lescure
Disclosure not yet available
J. M. Baena
Disclosure not yet available
J. Martin Liberal
Disclosure not yet available
S. Morales
Disclosure not yet available
J. I. Chacon
Disclosure not yet available
J. M. Lopez-Vega
Disclosure not yet available
I. Fernandez
Disclosure not yet available
D. Aguiar
Disclosure not yet available
A. Garcia-Palomo
Disclosure not yet available
R. M. Llorente
Disclosure not yet available
J. L. Barea
Disclosure not yet available
E. Alvarez
Disclosure not yet available
I. Blancas
Disclosure not yet available
Y. Fernandez
Disclosure not yet available
P. Sanchez Rovira
Disclosure not yet available
G. Vinyes
Disclosure not yet available